BioCentury | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

...NSCLC in combination with chemotherapy. Other notable additions to the NRDL include HCV drugs Epclusa sofosbuvir/velpatasvir...
BioCentury | Aug 28, 2019
Politics & Policy

Aug. 28 P&P Quick Takes: Liver failure warning for HCV drugs; plus FDA guidances and more

...glecaprevir/pibrentasvir from AbbVie Inc. (NYSE:ABBV), Zepatier grazoprevir/elbasvir from Merck & Co. Inc. (NYSE:MRK) and Vosevi sofosbuvir/velpatasvir/voxilaprevir...
BioCentury | Jun 27, 2019
Politics & Policy

June 26 P&P Quick Takes: FDA solicits comments on transparency programs; plus Louisiana’s HCV drug model and more

...Gilead Sciences Inc. (NASDAQ:GILD) subsidiary Asegua Therapeutics LLC to provide an authorized generic of Epclusa sofosbuvir/velpatasvir...
...smaller data sets than normally required. Jonathan Block, Associate Editor Epclusa (Brand), sofosbuvir/GS-5816 (Compound #), sofosbuvir/velpatasvir (Generic), Epclusa...
BioCentury | Apr 26, 2019
Company News

Express Scripts excludes Lilly's low cost insulin generic from preferred formulary

...offer a lower cost authorized alternative instead of a branded product from a manufacturer (see "Epclusa...
BioCentury | Mar 26, 2019
Company News

Louisiana picks Gilead's generics unit for HCV subscription model

...to partner with Gilead's generics subsidiary to access a generic version of HCV drug Epclusa sofosbuvir/velpatasvir...
...Inc. (NASDAQ:GILD) launched its Asegua Therapeutics LLC subsidiary in 2018 to offer generic versions of Epclusa...
...for a 12-week regimen, compared with a wholesale acquisition cost (WAC) of $74,760 for branded Epclusa...
BioCentury | Mar 5, 2019
Company News

Lilly offers cheaper insulin, pressuring competitors

...alirocumab. Meanwhile, Gilead Sciences Inc. (NASDAQ:GILD) announced in September authorized generics for HCV drugs Epclusa sofosbuvir/velpatasvir...
BioCentury | Jan 25, 2019
Clinical News

Cocrystal reports SVR12 rate of 67% for CC-31244 regimen

...infection who received 400 mg oral CC-31244 plus Epclusa sofosbuvir/velpatasvir for two weeks followed by Epclusa...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Roche (SIX:ROG; OTCQX:RHHBY) Actemra tocilizumab (RoActemra) $1,976.5 $1,598.2 $2,130.9 8% Gilead Sciences Inc. (NASDAQ:GILD) Epclusa sofosbuvir/velpatasvir...
...Australia, Canada, EU, Japan, U.S. in 2016; South Korea in 2017 Gilead Sciences Inc. (NASDAQ:GILD) Epclusa...
BioCentury | Dec 7, 2018
Clinical News

China approves Descovy, Harvoni, Hemlibra

...as part of an antiviral treatment regimen in patients ages 12 and older. Gilead's Epclusa sofosbuvir/velpatasvir...
...approved by NMPA in May to treat HCV genotypes 1-6 infection. In October, China added Epclusa...
BioCentury | Dec 4, 2018
Company News

China approves Descovy, Harvoni, Hemlibra

...as part of an antiviral treatment regimen in patients ages 12 and older. Gilead's Epclusa sofosbuvir/velpatasvir...
...approved by NMPA in May to treat HCV genotypes 1-6 infection. In October, China added Epclusa...
Items per page:
1 - 10 of 81